ABSTRACT Human recombinant tissue-type plasminogen activator (rt-PA) has been shown to be an effective and safe agent for coronary thrombolysis in patients with acute myocardial infarction. However, thrombolysis is associated with a high rate of acute reocclusion after discontinuation of rt-PA. The goals of the present study were to assess whether reocclusion after thrombolysis is caused by intracoronary platelet aggregation and to determine the role of thromboxane A2 (TxA2) No. 3, 678-684, 1988. CORONARY THROMBOLYSIS has recently received great attention for its potential reduction of the1 extent of necrosis after myocardial ischemia. Thrombolysis can be accomplished by infusion of streptoki-
nase or urokinase, which are systemic activators of the fibrinolytic system, or by infusion of the more clotselective, tissue-type plasminogen activator. The latter activates plasminogen primarily in the presence of fibrin, thus ensuring effective lysis of the fibrin clot without marked activation of circulating plasminogen.', 2 Recently, human tissue-type plasminogen activator has been produced by recombinant DNA technology (rt-PA) and has been used for coronary thrombolysis in patients with acute myocardial infarction. The results of different multicenter studies are available3-7 and there is general agreement that the rate of successful thrombolysis is higher with rt-PA than with intravenous streptokinase when the former is administered 4 to 5 hr after symptom onset and that reperfusion is accomplished with much less pronounced systemic fibrinogen depletion.3-7 However, a major problem has emerged from these initial trials; that is, despite a reperfusion frequency between 61% and 85%, acute coronary reocclusion developed in 20% to 45% of these patients, even when patients were fully heparinized. [3] [4] [5] [6] [7] Recently, a prolonged maintenance infusion of rt-PA has been shown to decrease the frequency of coronary reocclusion,8 but this problem is still far from being solved.
Fitzgerald et al.,9 in a recent preliminary report, measured urinary concentrations of 2,3-dinor thromboxane (Tx) B2 (as an index of platelet activation) in patients with acute myocardial infarction undergoing thrombolytic therapy. These authors found a significant increase in the urinary concentration of 2,3 dinor-TxB2 after thrombolysis, which probably reflects a marked platelet activation at the time of reperfusion.9
The goal of the present study was to test the hypothesis that intracoronary platelet activation after thrombolysis may lead to reocclusion in spite of adequate anticoagulant therapy. Additionally, we wanted to establish the role played by TxA2 and serotonin (5HT) secreted by platelets in mediating the reocclusion. A third goal of this study was to establish whether activated platelets present in the thrombus can c.~~~~~~~~~~A1~:~-::' :1
Coronary vasoconstriction. To demonstrate that platelet activation during thrombus formation can lead to coronaryvasoconstriction, five dogs were instrumented with a pair of ultrasonic crystals sutured on the adventitia of the LAD just below the copper coil. Intracoronary development of thrombus was associated with a striking decrease in LAD diastolic cross-sectional area. To differentiate changes in LAD diameter merely due to a reduction in LAD distending pressure from those caused by enhanced contraction of arterial smooth muscle cells, LAD dimensions obtained when the thrombus was occluding the artery were compared with the same variables during a complete LAD occlusion induced by means of a suture snare placed proximal to the Doppler flow probe before insertion of the copper coil. Occlusion of the LAD by the suture snare caused a reduction of LAD diastolic cross-sectional area of 20 + 4%, whereas formation of the thrombus was associated with a reduction of LAD cross-sectional area of 48 + 6% (p < .001, figure 3 ). In two of five dogs instrumented with the sonar crystals, rt-PA failed to lyse the intracoronary thrombus, one dog died of ventricular fibrillation during the LAD occlusion, and the remaining two dogs were entered in groups III and IV-B, respectively.
Fibrinolytic studies. Results of assays of fibrinogen, plasminogen, x2-antiplasmin, and FDPs are summarized in figure 4 . Fibrinogen, plasminogen, and (x2-antiplasmin levels decreased with reperfusion, but only modestly (to an average of 85%, 74%, and 69% of preinfusion values, respectively).
Partial thromboplastin times for the different groups at baseline and with immediate reocclusion and after 3 hr of reperfusion are summarized in table 1 increases in flow. These cyclical alterations in coronary blood flow were usually repeated a few times before a persistent coronary artery reocclusion occurred. The dynamic nature of this pattern makes it difficult to be detected by qualitative methods like coronary angiography, especially when angiographic examinations are repeated at relatively long time intervals.38 Administration of a full dose of heparin did not prevent the occurrence of either CFVs or reocclusion. However, antagonism of the TxA2/prostaglandin H2 and 5HT2 receptors with a bolus of SQ29548 and ketanserin was very effective in abolishing the CFVs after thrombolysis and delaying the occurrence of reocclusion: CFVs were abolished in six of six group II-A dogs and four of them had stable LAD flow throughout the experimental period (3 hr). In the remaining two dogs, the CFVs were also abolished, but reocclusion occurred earlier than 3 hr, probably because of a faster metabolism of the drug(s). In fact, when continuous infusions of LY53857 and SQ29548 were given after the initial bolus (group LI-B), the reocclu- 
